Related Experiment Video
Updated: Dec 12, 2025
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
TSLP as druggable target - a silver-lining for atopic diseases?
Partho Protim Adhikary1, Zheng Tan1, Brent D G Page2
1Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver Campus, Vancouver, BC V6T 1Z3, Canada.
Insights
Thymic stromal lymphopoietin (TSLP) is a key driver of atopic diseases like eczema and asthma. Inhibiting TSLP shows therapeutic promise for these common allergic conditions.
Area of Science:
- Immunology
- Allergy Research
- Dermatology
Background:
- Atopic diseases, including atopic dermatitis (AD), allergic rhinitis (AR), and allergic asthma (AA), are common allergic inflammatory conditions.
- These diseases often follow an 'atopic march,' starting in childhood and impacting quality of life and healthcare costs.
- They are typically characterized as T helper type 2 (Th2) cell-mediated inflammatory diseases.
Purpose of the Study:
- To review the role of thymic stromal lymphopoietin (TSLP) in the pathogenesis of atopic diseases.
- To discuss TSLP's autocrine and paracrine effects and its regulation of the tissue microenvironment.
- To highlight the rationale for targeting TSLP as a therapeutic strategy.
Main Methods:
- Literature review focusing on TSLP's function in atopic diseases.
- Analysis of experimental data on TSLP inhibition and knockout models.
- Discussion of TSLP's role as a master regulator of type 2 immune responses.
Main Results:
- TSLP is an epithelium-derived cytokine that activates immune and non-immune cells.
- TSLP is identified as a master regulator of type 2 immune responses and is implicated in driving atopic diseases.
- Experimental inhibition or knockout of TSLP signaling demonstrates significant therapeutic potential.
Conclusions:
- TSLP plays a central role in the pathogenesis of atopic diseases.
- Understanding TSLP's mechanisms provides a strong rationale for its development as a druggable target.
- Targeting TSLP offers a promising therapeutic avenue for managing allergic inflammatory conditions.
Abstract:
Atopic diseases refer to common allergic inflammatory diseases such as atopic dermatitis (AD), allergic rhinitis (AR), and allergic asthma (AA). AD often develops in early childhood and may herald the onset of other allergic disorders such as food allergy (FA), AR, and AA. This progression of the disease is also known as the atopic march, and it goes hand in hand with a significantly impaired quality of life as well as a significant economic burden. Atopic diseases usually are considered as T helper type 2 (Th2) cell-mediated inflammatory diseases. Thymic stromal lymphopoietin (TSLP), an epithelium-derived pro-inflammatory cytokine, activates distinct immune and non-immune cells. It has been shown to be a master regulator of type 2 immune responses and atopic diseases. In experimental settings, the inhibition or knockout of TSLP signaling has shown great therapeutic potential. This, in conjunction with the increasing knowledge about the central role of TSLP in the pathogenesis of atopic diseases, has sparked an interest in TSLP as a druggable target. In this review, we will discuss the autocrine and paracrine effects of TSLP, how it regulates the tissue microenvironment and drives atopic diseases, which provide the rationale for the increasing interest in TSLP as a druggable target.
More Related Videos
09:51Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
17:35A Microplate Assay to Assess Chemical Effects on RBL-2H3 Mast Cell Degranulation: Effects of Triclosan without Use of an Organic Solvent
Published on: November 1, 2013
